2023年1月17日

由分享本文提供的新闻分享本文关键试验达到了步态速度改善的主要终点。MedRhythms计划在不久的将来在一个重大会议上展示完整的研究结果。波特兰，缅因州，2023年1月17日/美通社/——MedRhythms今天宣布，该公司对MR-001的关键试验成功完成，MR-001是一种治疗慢性中风步态缺陷的新型数字干预开发，已达到其主要终点。MedRhythms的首席执行官兼联合创始人布莱恩·哈里斯(Brian Harris)说:“至少有350万慢性中风幸存者患有步态缺陷，目前在美国没有标准的治疗措施。”“我们在慢性中风中的关键试验的结果表明，我们的产品可以帮助解决这一未满足的改善步行的需求。成功完成MR-001的关键试验是一个重要的里程碑，代表着我们在将这一解决方案提供给需要它的患者方面取得了重大进展。”这项多地点随机对照试验在美国8家顶级康复医院和研究机构进行，包括雪莉·瑞安能力实验室、斯波尔丁康复医院、波士顿大学神经运动恢复实验室、凯斯勒基金会、西奈山卫生系统、中庭健康和北卡罗来纳大学教堂山分校。该试验包括成年慢性中风幸存者，他们在为期五周的干预期内每周参加三次30分钟的训练。研究参与者要么使用MR-001，要么作为积极对照组的一部分。MedRhythms打算将这一重要的临床数据提交给一份科学杂志进行同行评审，并在今年晚些时候的一次重大会议上展示这些数据。 MedRhythms has a robust pipeline of next-generation neurotherapeutics in active development. The company aims to bring these solutions to a wide range of patients with neurologic injury and disease. MR-001, in development to treat chronic stroke gait deficits, is anticipated to be the first product the company brings to market. Other advanced pipeline programs include MR-004, a novel, investigational prescription digital therapeutic targeting gait deficits in multiple sclerosis for which the company entered into a license agreement with Biogen . Furthermore, the company has initiated feasibility studies of MR-005 , in development to treat gait deficits in Parkinson's disease, and MR-010 , in development to treat gait deficits in post-acute stroke. About MedRhythms MedRhythms is pioneering the development of next-generation neurotherapeutics designed to improve walking, mobility and related functional outcomes via a proprietary, patented technology platform. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. The company is developing a pipeline of digital therapeutics across a range of neurological conditions, including stroke, multiple sclerosis and Parkinson's disease. The company's pipeline product for chronic stroke walking deficits received Breakthrough Device designation in 2020 and the company raised a Series B financing round in 2021 led by Morningside Ventures and Advantage Capital. MedRhythms is headquartered in Portland, Maine. For more information, visit www.medrhythms.com . Forward-Looking Statements THIS MANAGEMENT COMMENTARY CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO THE COMPANY THAT ARE BASED ON INFORMATION AVAILABLE TO US AS OF THE DATE HEREOF. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS ABOUT THE COMPANY'S BELIEFS, DESIGNS, ANTICIPATION, AIMS, GOALS, EXPECTATIONS AND POTENTIAL RESULTS ARE FORWARD-LOOKING STATEMENTS. IN ADDITION, THE WORDS "WILL," "MAY," "BELIEVE," "ANTICIPATE," "INTEND," "ESTIMATE," "EXPECT," "PROJECT," "PLAN," "SHOULD," "COULD," AND SIMILAR EXPRESSIONS, AND THEIR VARIATIONS AND NEGATIVES, AS THEY RELATE TO THE COMPANY OR THE FUTURE PERFORMANCE OF THE COMPANY, ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. SUCH FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES, ASSUMPTIONS AND OTHER IMPORTANT FACTORS THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD LOOKING STATEMENTS. THIS MANAGEMENT COMMENTARY SPEAKS ONLY AS OF THE DATE HEREOF AND THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO UPDATE THIS COMMENTARY IN THE FUTURE. Contact: